Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471767 · ClinicalTrials.gov registry record · Phase 2
AXS-05 Phase II Trial on Smoking Behavior
A Phase 2 study of Smoking Cessation and Nicotine Dependence, sponsored by James Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT03471767 is a Phase 2 study of Smoking Cessation and Nicotine Dependence that has completed, run by James Davis. The registered enrollment target is 58 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03471767, a Phase 2 study of Smoking Cessation and Nicotine Dependence, has completed, sponsored by James Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
Conditions Studied
Interventions
- DRUG AXS-05
- DRUG Bupropion SR
Study Locations (1)
North Carolina
- Duke Center for Smoking Cessation - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-03-25 |
| Est. Completion | 2019-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471767
The ClinicalTrials.gov registry entry for NCT03471767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (88% lower). The listed sponsor is James Davis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which AXS-05 is the first listed.
NCT03471767 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03471767 about?
NCT03471767 is a clinical study titled "AXS-05 Phase II Trial on Smoking Behavior". This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
What is the current status of trial NCT03471767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-03-25. Estimated completion is 2019-03-31.
What conditions does trial NCT03471767 study?
This clinical trial studies the following conditions: Smoking Cessation, Nicotine Dependence, Smoking, Cigarette.
What interventions are being tested in trial NCT03471767?
The interventions under investigation include: AXS-05 (DRUG), Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT03471767?
This trial is sponsored by James Davis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03471767 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.